Novel information on the non-neuronal cholinergic system in orthopedics provides new possible treatment strategies for inflammatory and degenerative diseases by Forsgren, Sture et al.
Orthopedic Reviews 2009; volume 1:exxxx
[Orthopedic Reviews 2009; 1:e11] [page 39]
Novel information on the 
non-neuronal cholinergic
system in orthopedics provides
new possible treatment
strategies for inflammatory and
degenerative diseases
Sture Forsgren,
1 Håkan Alfredson,
2
Dennis Bjur,
1 Solbritt Rantapää-
Dahlqvist,
3 Örjan Norrgård,
4 Tore Dalén,
5
Patrik Danielson
1
1Dept. of Integrative Medical Biology,
Anatomy, Umeå University, Umeå,
Sweden; 
2Dept. of Surgical and Perioperative
Sciences, Sports Medicine, Umeå
University, Umeå, Sweden; 
3Dept. of Public Health and Clinical
Medicine, Rheumatology, Umeå
University, Umeå, Sweden; 
4Dept. of Surgical and Perioperative
Sciences, Surgery, Umeå University,
Umeå, Sweden; 
5Dept. of Surgical and Perioperative
Sciences, Orthopaedics, Umeå University,
Umeå, Sweden
Abstract 
Anti-cholinergic  agents  are  used  in  the
treatment  of  several  pathological  conditions.
Therapy  regimens  aimed  at  up-regulating
cholinergic functions, such as treatment with
acetylcholinesterase  inhibitors,  are  also  cur-
rently prescribed. It is now known that not only
is there a neuronal cholinergic system but also
a non-neuronal cholinergic system in various
parts of the body. Therefore, interference with
the  effects  of  acetylcholine  (ACh)  brought
about by the local production and release of
ACh  should  also  be  considered.  Locally  pro-
duced ACh may have proliferative, angiogenic,
wound-healing, and immunomodulatory func-
tions.  Interestingly,  cholinergic  stimulation
may lead to anti-inflammatory effects. Within
this  review,  new  findings  for  the  locomotor
system  of  a  more  widespread  non-neuronal
cholinergic  system  than  previously  expected
will be discussed in relation to possible new
treatment strategies. The conditions discussed
are painful and degenerative tendon disease
(tendinopathy/tendinosis), rheumatoid arthri-
tis, and osteoarthritis. 
New aspects on the usefulness
of interference with 
acetylcholine effects: basis for
the present review
Medications interfering with the effects of
acetylcholine (ACh) are frequently used today.
Anti-cholinergic agents are widely used in the
management of overactive urinary bladder and
of  obstructive  lung  disease.  However,  treat-
ments leading to the upregulation of choliner-
gic activity are increasingly applied. New pos-
sibilities  for  interference  with  cholinergic
effects are currently discussed. This is related
to the existence of a widespread non-neuronal
cholinergic system. 
The  present  review  summarizes  hitherto
known aspects of possible treatment strategies
concerning  interference  with  cholinergic
effects. That includes inflammation in general,
cancer, and pain conditions. However, major
focus  is  devoted  to  discussions  concerning
conditions afflicting the locomotor system and
for which a non-neuronal cholinergic system
has been recently shown to exist. More specif-
ically, the conditions discussed are rheumatoid
arthritis  (RA)  and  osteoarthritis  (OA),  and
chronically  painful  tendons  (tendinopathy)
with degenerative-like tissue changes (tendi-
nosis). Tendinopathy is a condition in which
there is chronic pain in a tender portion of the
tendon. The tendons most frequently affected
are the Achilles and patellar tendons. When, in
addition to chronic pain, there are structural
tissue changes of a degenerative-like nature,
as seen by ultrasonography or magnetic reso-
nance imaging (MRI), or by histological exam-
ination, the condition is called tendinosis. In
the following text, our recent observations con-
cerning Achilles and patellar tendinosis will be
discussed. Nothing at all has been previously
known concerning the existence of a non-neu-
ronal cholinergic system in tendinosis or the
synovial tissue of patients with RA or OA. The
current review will, therefore, give new direc-
tions  concerning  the  cholinergic  system  in
these conditions. 
Acetylcholine production and
acetylcholine receptors 
ACh  was  the  first  neurotransmitter  to  be
identified. It is synthesized from choline and
acetyl-CoA  via  the  activity  of  choline  acetyl-
transferase (ChAT).
1,2 In addition to production
via ChAT, ACh can be produced by carnitine
acetyltransferase (CarAT). ACh is then trans-
ferred to synpatic vesicles by vesicular acetyl-
choline transporter (VAChT).
3 ACh is degraded
by  cholinesterases.
4 It  is  converted  into  the
inactive  metabolites  choline  and  acetate  by
acetylcholinesterase (AChE). It is well known
that the effects of ACh are mediated via mus-
carinic (G-protein coupled) and nicotinic (lig-
and-gated ion channels) ACh receptors.
5 The
muscarinic  ACh  receptors  (mAChRs)  are
metabotrophic,  and  are  stimulated  by  mus-
carine  and  ACh,  whilst  the  nicotinic  ACh
receptors are ionotrophic receptors stimulated
by nicotine and ACh. Muscarine is an alkaloid
extracted from certain mushrooms, and nico-
tine is an alkaloid substance found in tobacco.
Five subtypes of mAChRs have been identified
(M1-M5),  each  with  different  functions  and
properties.
6 Certain  features  regarding  the
expression patterns of the mAChRs in regions
outside  the  central  nervous  system  are  well
known, including the fact that the M2 receptor
subtype  comprises  more  than  90%  of  the
mAChRs in the heart.
7 The main ACh receptor
in the smooth muscle of the gastrointestinal
tract is the M2 receptor.
8 The mAChRs associat-
ed with smooth muscle cells are predominant-
ly of the M2 and M3 subtypes. The nicotinic
receptors (nAChRs) are pentameric complexes
consisting of a large number of different alpha-
and beta-subunits.
9 The various nAChRs have
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characterized nAChR, which, due to its rela-
tionship to immune functions, is further dis-
cussed below, is the α7nAChR. 
There are both neuronal and
non-neuronal cholinergic 
systems
ACh is a neurotransmitter in the central, as
well as in the peripheral, nervous system. It is
a major transmitter in the autonomic nervous
system,  the  principal  transmitter  of  the
parasympathetic  part  of  this  system,  and  a
neurotransmitter in all autonomic ganglia. On
the  other  hand,  nerve-related  reactions  for
ChAT or CarAT have, to the best of our knowl-
edge, not been shown in synovial tissues of
joints or for tendon tissue. It is well known that
ACh synthesis is not only restricted to neu-
rons; there is also a non-neuronal cholinergic
system. Accordingly, ACh is produced in sur-
face epithelia, such as those of the airways
10
and  the  intestine.
11,12 Furthermore,  the  ker-
atinocytes of the skin
13 and cells in the urothe-
lium
14,15 are also ACh-producing. Additionally,
cells in blood vessel walls,
16,17 as well as fibrob-
lasts in various locations,
18 show production of
ACh. An occurrence of expression of non-neu-
ronal ACh and ACh-synthesizing activity has
also  previously  been  shown  for  a  variety  of
plants  and  organisms  including  fungi,  algae
and bacteria.
19,20 The occurrence of a non-neu-
ronal ACh production includes the situation for
certain cancer cells and for inflammatory cells.
It has been shown that ACh is synthesized by
cells of small lung cell carcinoma,
21,22 colon can-
cer,
23,24 and  breast  cancer.
25 Furthermore,
inflammatory  cells  have  been  shown  to  pro-
duce ACh.
26The effects of ACh on the functions
of inflammatory cells do occur principally via
effects on the α7nAChR. Recently we found
that the tendon cells (tenocytes) in patellar
27,28
and Achilles
29 tendons showed evidence of ACh
production. This was observed by analysis of
ChAT and VAChT reactions at both protein and
mRNA  level.  We  have  furthermore  observed
that mononuclear- and fibroblast-like cells of
the synovium of patients with severe RA and
OA  show  ChAT  expression.
30 We  have  also
made original findings regarding the colon of
patients  with  ulcerative  colitis  (UC).  In  the
colon from patients with UC, cells, including
inflammatory cells in the lamina propria, cells
of  the  blood  vessel  walls,  and  cells  of  the
epithelial layer, were identified as being capa-
ble of ACh synthesis.
31In the following text, the
aspects of the non-cholinergic effects in the
locomotor  system  are  focused  upon.  In  our
recent studies on the synovium of joints, and
tendons of man we found a marked occurrence
of the M2 type of mAChRs. Immunoreactions
for the M2 receptor were observed for the teno-
cytes, nerves, and blood vessel walls of Achilles
and patellar tendons,
27-29 and were also noted in
the synovial tissue from patients with RA as
well  as  from  those  with  OA.  An  interesting
aspect noted is the fact that the evidence for a
non-neuronal  cholinergic  system  in  tendon
and synovial tissues is particularly apparent in
pathological  situations.  Thus,  the  levels  of
expression of enzymes catalyzing ACh produc-
tion,  as  well  as  the  levels  of  expressions  of
mAChRs, were much more evidently seen in
deranged  and  chronically  painful  tendinosis
tendons than in normal tendons.
27-29A schemat-
ic  drawing  summarizing  the  non-neuronal
cholinergic system of human tendinosis ten-
dons  is  shown  in  Figure  1.  Furthermore,
expression of enzyme related to ACh produc-
tion was marked in specimens of the synovial
tissue of knee joints of RA patients exhibiting
pronounced  invasion  of  mononuclear-like
cells,  as  well  as  showing  the  occurrence  of
numerous  fibroblast-like  cells.
30 Such  an
expression  was  also  noted  for  mononuclear-
like and fibroblast-like cells in specimens of
the  synovial  tissue  of  OA  patients.
30
Concerning the synovial specimens of both RA
and OA patients, these corresponded to speci-
mens of biopsies taken during prosthesis oper-
ations.
The functions of the neuronal
and non-neuronal cholinergic
systems 
Effects in general
The  responses  in  the  effector  organs  to
impulses leading to release and effects of ACh
from the autonomic nervous system are well
described in textbooks. Typical features are a
decrease  in  heart  rate,  contraction  of  the
sphincter  muscle  of  the  iris,  contraction  of
bronchial  muscles,  and  increased  exocrine
secretion from the pancreas. These are effects
of ACh released from postganglionic parasym-
pathetic  nerve  fibres.  In  the  intestine,  for
example, it is well known that stimulation by
ACh leads to an increase in smooth muscle
contraction and a stimulation of secretion. 
Based on results of studies on experimental
animals,  it  has  been  theorized  that  ACh
released from cholinergic nerves is involved in
vasoregulation  in  joints.
32 However,  as
described above, it has not yet been proven
whether cholinergic nerves are present in the
synovial tissues. There are no reports of effects
of neuronally-released ACh within tendons.
The  function  of  non-neuronal  ACh  is  in
Review
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Figure 1. Schematic drawing of human tendon tissue showing the occurrence of a non-
neuronal cholinergic system in tendinosis. Violet dots represent acetylcholine (ACh) that
is locally produced in tenocytes of pathological appearance (unfilled arrow). Normal
looking tenocytes (filled arrow) do not produce ACh.
27-29 ACh can influence 1) nerves, 2)
cells of blood vessel walls, and 3) the tenocytes themselves. These structures have been
shown to be supplied with muscarinic ACh receptors of subtype M2 (M2R).
27-29 Image by
Gustav Andersson.principle  related  to  autocrine/paracrine
actions.
10,20 Thus, the cells types producing ACh
are also equipped with receptors for this sub-
stance. That includes, for example, the situa-
tion for the non-neuronal cholinergic system
of the granulose cells in the human ovary.
33
More precisely, the functions of the non-neu-
ronal cholinergic system are mainly related to
effects on differentiation and growth, secre-
tion, barrier functions, and immuno-modula-
tion (for reviews, see Kawashima and Fujii
34
and Wessler and Kirkpatrick
20). Important ACh
effects are those on angiogenesis,
35,36 prolifera-
tion rates,
13,37,38 and wound healing.
13,39
It  is  frequently  emphasized  that  the  ACh
that is produced by the inflammatory cells has
effects  on  those  cells,  suggesting  that  ACh
modulates the activity of inflammatory cells via
autocrine  and  paracrine  loops.
40 The  influ-
ences of ACh on the inflammatory cells may be
related to the time scale with acute stimula-
tion leading to proinflammatory effects whilst
chronic  stimulation,  on  the  other  hand,  has
anti-inflammatory effects.
40 The overwhelming
majority of studies on ACh effects in relation to
inflammation  do,  nevertheless,  support  the
view that ACh has anti-inflammatory effects
(see further below). 
The cholinergic anti-inflammatory
pathway
Based  on  findings  by  several  groups,  the
existence  of  a  so-called  ‘cholinergic  anti-
inflammatory pathway’ has been proposed.
41-44
This implies that ACh, released in response to
activation  of  nerve  fibres  like  those  of  the
vagal  nerve,  has  effects  on  local  inflamma-
tion.
45 Electrical stimulation of the vagus nerve
leads to inhibition in the synthesis of TNFα,
and  attenuates  the  release  of  different  pro-
inflammatory  cytokines.
41,42 The  vagal  anti-
inflammatory effects are known to be mediat-
ed  by  the  Jak2/STAT3  signaling  on
macrophages
42 or  via  inhibition  of  the  tran-
scription  factor  NF-kappaB.
46 It  should  be
remembered that there are variations between
different organs concerning the occurrence of
anti-inflammatory  effects  via  stimulation  of
the  vagus  nerve.  Such  a  stimulation  has  a
marked  anti-inflammatory  effect  within  the
gastrointestinal  tract,
42 but  a  limited  anti-
inflammatory effect in the lungs.
41
The spleen has been shown to be important
in mediating the antiinflammatory effects that
occur in response to electrical stimulation of
the vagus nerve.
47
The cholinergic antiinflammatory pathway
is shown to regulate the production of TNFαby
macrophages via effects on preganglionic neu-
rons related to the vagus nerve and via effects
on postganglionic neurons originating in the
celiac-superior mesenteric plexus and project-
ing  within  the  splenic  nerve.
48 The  findings
that muscarinic receptor antagonists mediate
anti-inflammatory actions favor the suggestion
that there is a cholinergic anti-inflammatory
pathway.
49 Nevertheless,  it  is  the  α7nAChR
that is the ACh receptor, that is the essential
receptor for the inhibition of cytokine synthe-
sis  via  the  cholinergic  anti-inflammmatory
pathway.
50,51 One structure that may be a target
for anti-inflammatory cholinergic mediators is
the endothelium, as the endothelium is a key
regulator  of  leukocyte  trafficking  during
inflammation.
52
The occurrence of anti-inflammatory effects
of  the  parasympathetic  nervous  system  has
been shown in different ways. The anti-inflam-
matory effects that cholecystokinin is known to
have are thus mediated by the vagus nerve
53
and  activation  of  the  vagus  nerve  prevents
manipulation-induced  inflammation  of  the
smooth muscle layers.
42 Interestingly, it is sug-
gested that anti-inflammatory effects not only
occur via the neuronal but also the non-neu-
ronal  cholinergic  system,
40 and  furthermore,
that  the  release  of  non-neuronal  ACh  from
local cells, such as inflammatory cells, is trig-
gered by neuronally-released ACh.
20
Changes in magnitude of the
non-neuronal cholinergic
system: occurrence of 
up- and downregulations
The new information obtained in our labora-
tory shows that there is a more clearly marked
non-neuronal cholinergic system in tendinosis
tendons  than  in  normal  tendons.
27-29 Further-
more, there is an extensive expression of M2
receptors  in  tendinosis  tendons,  but  clearly
less so in normal tendons. It is also a fact that
the non-neuronal cholinergic system is repre-
sented to a large extent in the synovial tissue
in RA if the tissue is heavily infiltrated with
inflammatory cells and fibroblasts.
30 Many of
these cells show expression for the ACh-syn-
thesizing  enzyme  ChAT.  Upregulation  of  the
cholinergic system also occurs in other situa-
tions, for example such an upregulation has
been  reported  for  cancer  cells.
22 It  has  also
been shown that the cholinergic system is up-
regulated in the superficial skin in atopic der-
matitis.
54 However, the situation is apparently
different  in  certain  acute  situations.  Thus,
there is a decrease in non-neuronal ACh syn-
thesis  in  an  acute  model  of  allergic  airway
inflammation.
55 Whether upregulation of ACh
production in non-neuronal cells is of positive
or  negative  character  for  the  tissue  is  only
partly  known.  Obtaining  a  reduction  in  pul-
monary ACh content in experimental studies
of lung injury was considered to be of positive
character, protecting the lung tissue.
56 Further
aspects on this question are discussed below.
For  many  conditions  it  seems  as  if  an
increased  ACh  effect  would  be  welcome.
Cancer  is  a  major  exception  (see  further
below).
Treatments leading to interfer-
ence with cholinergic effects
General aspects 
Anti-cholinergics are useful in certain clini-
cal situations. However, treatments leading to
cholinergic upregulation may also have a posi-
tive  outcome.  Thus,  as  will  be  further  dis-
cussed below, treatment with AChE inhibitors,
leading  to  increased  ACh  levels,  has  been
found  to  be  a  treatment  of  choice  in
Alzheimer’s disease. Furthermore, the concept
of the cholinergic anti-inflammatory pathway
implies  that  inducing  increased  ACh  effects
may be favorable for inflammatory situations.
There are also other reports suggesting that
increased ACh effects may be helpful clinically.
The results of recent studies on cystic fibrosis
suggest that treatment with muscarinic recep-
tor agonists may be beneficial.
57 Furthermore,
in a recent experimental study on acute aller-
gic airway inflammation, the occurrence of a
downregulations of non-neuronal ACh synthe-
sis  and  release  machinery  was  furthermore
suggested to contribute to epithelial shedding
and ciliated dysfunction.
55
Treatment with AChE inhibitors 
Over recent decades, a number of therapies
aimed at up-regulating cholinergic function
have been tested as treatment for Alzheimer’s
disease, with AChE inhibitors being the group
of substances that are best developed (for a
review, see Shah et al.
58). Thus, compounds
frequently used nowadays for the treatment of
mild  forms  of  this  disease  are  blockers  of
AChE activity
59. The basis for this is the well-
known fact that there is a loss of cholinergic
function  in  Alzheimer’s  disease  and  that
AChE is the enzyme that degrades ACh. AChE
inhibitors  are  also  used  in  myasthenia
gravis.
60 Cholinergic agonism, via administra-
tion of an AChE inhibitor, has also been test-
ed for multiple sclerosis (MS) patients, and
this agonism was hereby shown to alter cog-
nitive processing and to enhance brain func-
tional connectivity.
61 In studies on experimen-
tal autoimmune encephalomyelitis, which is
a model for the pathology of MS, it was found
that treatment with an AChE inhibitor sup-
pressed  neuroinflammation  and  showed
immunomodulatory activity.
62 A scheme of the
anti-inflammatory outcome that is achieved
using  AChE  inhibitors  during  experimental
neuroinflammation has recently been depict-
Review
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63 These
authors  found  that  the  AChE  inhibitors
induced cholinergic upregulation and effects
on  the  neuroinflammation  via  α7nAChR
expressing cells.
63
It has been shown that treatment of mice
with AChE inhibitors attenuates the produc-
tion  of  interleukin-1beta  in  both  the  hip-
pocampus and blood, showing that choliner-
gic enhancement produces both central and
peripheral  anti-inflammatory  effects.
64 The
results of studies on endotoxemia also sug-
gest  that  centrally  acting  cholinergic
enhancers may have anti-inflammatory prop-
erties.
43 Inhibition  of  brain  AChE  via  treat-
ment with AChE inhibitors has recently been
shown  to  suppress  systemic  inflammation,
suggesting that the brain’s cholinergic mus-
carinic networks communicate with the anti-
inflammatory  pathway  thereby  suppressing
peripheral inflammation.
65
Obtaining of cholinergic 
anti-inflammatory effects via the
nicotinic pathway 
Nicotine is more active than ACh in inhibit-
ing the production of pro-inflammatory media-
tors by macrophages.
51 The anti-inflammatory
effects of nicotine on these cells can be coun-
teracted  by  selective  α7-antagonists.
45
Influences on the nAChRs via nicotine have
been tested in clinical situations, especially in
UC. The therapeutic benefit is, however, limit-
ed,  and  troublesome  side-effects  of  nicotine
occur.
66
The  effects  of  ACh  stimulation  on  the
α7nAChR may, due to the known relationship
between this receptor and inflammation, be of
importance  in  inflammatory  conditions.
Accordingly,  it  is  suggested  that  α7nAChRs
play a critical role in the protection against the
development of neurodegenerative diseases.
67
The use of selective α7nAChR agonists has,
furthermore,  been  shown  to  be  of  value  in
order  to  diminish  cytokine  production  by
macrophages and inflammation in several ani-
mal models of inflammation (for a review, see
de Jonge and Ulloa
68). 
Possible usefulness of 
interference with cholinergic
effects in certain conditions
Cancer
It is well-known that ACh receptors, includ-
ing both mAChRs and nAChRs, are functional-
ly present on certain cancer cells (for reviews,
see Paleari et al. 2008
69 and Song and Spindel
2008
22). This includes the cancer cells in small
cell lung carcinoma (SCLC), in which the cells
have  been  shown  to  synthesize  and  secrete
ACh,  and  to  be  equipped  with  mAChRs  and
nAChRs.
21 The M3 mAChR is over-expressed in
tumor cells of colon cancer.
70 In recent studies
it was shown that cells of the human colon can-
cer cell line HT-29 express the α7nAChR sub-
type.
24
It is known that the level of cholinergic sig-
naling is up-regulated in squamous cell carci-
noma,
22 and that stimulation of cells of mam-
mary adenocarcinoma cell lines with carbacol
increases their proliferation via M3 mAChR-
mediated  pathways.
71 It  is  suggested  that
mAChR antagonists may be useful adjuncts for
SCLC treatment,
21 and that blocking choliner-
gic signaling can limit the growth of squamous
lung carcinoma.
22 In accordance with the latter
suggestion, α7nAChR antagonists are antici-
pated to be a useful adjunct to the treatment of
such lung cancer.
72 The potential implications
of mAChRs in tumor progression and the pos-
sible use of muscarinic ligands in cancer ther-
apy  have  been  recently  reviewed.
73 The  fact
that cholinergic signaling is increased in cer-
tain cancers may reinforce the usefulness of
ACh blockade in these situations. It should be
stressed that stimulation of ACh leads to an
increase in cell proliferation
13,38 and to angio-
genesis.
36 The fact that ACh stimulation leads
to these features indeed favors the proposal
that blocking the effects of ACh may be benefi-
cial  in  cancers  showing  an  upregulation  of
cholinergic features. The fact that ACh inhibits
long-term hypoxia-induced apoptosis in mouse
stem cells,
74 and that nicotine increases cell
growth of a human colon cancer cell line, the
effect being depressed by an antagonist to the
α7nAChR,
24,75 also supports such a suggestion. 
Pain conditions
Interference  with  cholinergic  effects  may
have  some  relevance  in  relation  to  pain.
76,77
ACh  has  been  shown  to  induce  pain  when
applied to human skin.
78 However, cholinergic
effects  have  mainly  been  found  to  be  of  an
analgesic nature. Administration of mucarinic
agonists with effects on the central nervous
system can thus induce pronounced analgesic
effects.
77 Inflammatory joint pain can be partly
modulated  via  muscarinic  cholinergic  recep-
tors as shown in animal model studies,
79 e.g.,
analgesia induced by an AChE inhibitor has
been shown in a rat model.
80 The possible use-
fulness of targeting the mAChRs in antinoci-
ception has been recently discussed.
73
Chronic pain is the major symptomatic fea-
ture of tendinosis, and the pain mechanisms
for this disease are still largely unknown and
frequently discussed.
81 The aspects of tendon
pain in relation to the non-neuronal choliner-
gic  system  in  tendon  tissue  are  discussed
below. 
Tendinosis
In tendinosis, a non-inflammatory degener-
ative-like condition in which an increase in
tissue cells (tenocytes) and a hypervascularity/
neovascularization are typical phenomena,
82-84
it is likely that the proliferation of tenocytes
and the angiogenesis are related to an initial
tissue healing process in response to mechan-
ically induced micro-trauma. The tenocytes are
the cells that produce not only the collagen but
also various signal substances that are likely to
have  important  roles  in  the  turnover  of  the
extracellular matrix.
85 However, the blood ves-
sel changes may in the long run be a drawback.
Thus, hypervascularity and neovascularization
have  been  correlated  with  the  chronic  pain
experienced  in  tendinosis,
86 and  new  treat-
ment  methods  focusing  on  destroying  the
region  with  hypervascularity/neovasculariza-
tion by injection of the sclerosing substance
polidocanol have not only led to pain relief but
in  the  long-term  perspective  also  to  tendon
remodeling.
87-89
Given  the  information  that  tenocytes  of
tendinosis  tendons  produce  ACh,  and  that
there are mAChRs on the tenocytes and on the
cells of the blood vessel walls,
27,29 it is possible
that the non-neuronal ACh might have effects
on cell proliferation, collagen production, and
blood  vessel  regulation  in  tendinosis.  It  is
already known that ACh can increase the pro-
liferation  of  myofibroblastic  cells,
90 and  that
stimulation of ACh receptors on certain fibro-
blasts may augment collagen accumulation.
91
Also, as previously discussed, agonists of ACh
receptors  are  known  to  promote  angiogene-
sis.
36 It might be that treatments that lead to
increased cholinergic effects on the tenocytes
and the blood vessels might be attractive in
early stages of tendinosis. At these stages, an
increased  tenocyte  population  and  an
increased vascularity are likely to be of value
for the tendon. On the other hand, less cholin-
ergic influences on the blood vessels may be
desirable in chronic stages. It may also be that
an excess of tenocytes is a drawback for ten-
don function in the long run. The functional
importance of the ACh production in the teno-
cytes, and the marked existence of mAChRs on
these cells, as well as on blood vessel walls in
tendinosis  tendons,  should  be  further
explored. 
One should bear in mind that signal sub-
stances other than ACh, e.g., catecholamines,
92-94
and glutamate,
95 are produced by tenocytes in
tendinosis tendons and that the tenocytes are
equipped with receptors for various signal sub-
stances. Furthermore, there is a production of
neurotrophins in the tenocytes and the exis-
tence  of  the  p75  neurotrophin  receptor  in
these  cells.
96 This  means  that  interactions
between a number of substances that are deliv-
ered locally have to be considered. Some of the
substances produced, such as glutamate, are
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healing.  It  may  be  that  interference  with
cholinergic effects should be combined with
interference with the effects of other type(s)
of signal substances. 
To further understand the pain mechanisms
in tendinosis, the newly developed treatments
for this condition should be considered. The
sclerosing  injection  treatment,  mentioned
above,  targets  the  regions  of  tendinosis
Achilles and patellar tendons showing patho-
logically high blood flow.
87,88 These regions con-
form to outer parts of the tendons (the para-
tendinous connective tissue). Our findings of
an abundance of mAChRs in blood vessel walls
in tendinosis tendons
27,29 show that these ves-
sels are under marked cholinergic influence.
Nevertheless, it is probable that the pain-relief
is not primarily related to effects on the vascu-
lature but to effects on the nerves located close
to the blood vessels. Consequently, it is inter-
esting to note that we have also found mAChRs
on nerve fascicles in the tendinosis tendons.
27
To what extent the ACh effects, and those of
other  nerve  signal  substances  such  as  sub-
stance P in the sensory innervation, are relat-
ed to the pain symptoms in tendinosis must,
however, await further studies. 
Rheumatoid arthritis 
It is evident that the infiltrating inflammato-
ry cells, as well as the proliferating fibroblast-
like cells, in the synovium become part of a
non-neuronal cholinergic system in advanced
RA, as verified by the expression of enzyme
related to ACh production (ChAT). Such cells
in synovial specimens of OA patients also show
this feature. In both conditions, the existence
of ChAT production was noted in specimens
obtained after prosthesis operations. It may be
that the existence of ACh production in these
cells is related to trophic/modulatory and anti-
inflammatory, rather than damaging, effects in
the chronic stages of RA and OA. This could be
seen as an attempt to balance the production
of pro-inflammatory substances. 
A favorable outcome in arthritis via cholin-
ergic agonism has recently been shown exper-
imentally  in  mice.  Based  on  evaluating  the
effect of adding nicotine to the drinking water
of mice with collagen-induced arthritis (CIA),
the effects of vagotomy and the effects of treat-
ment with an α7nAChR agonist, the authors
concluded that there exists a cholinergic anti-
inflammatory  pathway  in  the  murine  CIA
model of RA.
97 An existence of α7nAChRs on
the fibroblast-like synoviocytes in human syn-
ovium has also been shown and ACh was found
to inhibit cytokine expression through a post-
transcriptional mechanism in these cells.
98 In
the study by Waldburger and collaborators,
98 it
was suggested that the α7nAChR is a potential
therapeutic target for RA. In studies on a rat
model of knee joint inflammation published as
early as 1998, it was shown that a centrally
administered AChE inhibitor, neostigmine, led
to enhanced levels of endogenous ACh, which
in turn functioned as an analgesia-modulating
compound at both central and peripheral sites
of inflammatory pain.
80
It  can  be  speculated  that  treatments  that
contribute to additional ACh effects could be
useful in order to prevent the establishment of
a marked derangement and damage of synovial
tissues in advanced stages of RA and OA. Such
interference would, thus, possibly lead to anti-
inflammatory  features.  In  accordance  with
such a suggestion are the recent findings by
Goldstein and collaborators.
99 In their studies it
was  shown  that  the  occurrence  of  a  dimin-
ished  cholinergic  anti-inflammatory  pathway
activity is associated with increased levels of
high mobility group box-1, a cytokine that is
implicated in the pathogenesis of arthritis,
100
in patients with RA.
99
Conclusions
In summary, the basis for the present review
is the fact that new indications for interfer-
ence with cholinergic effects should be consid-
ered. The reason is that there exists a wide-
spread local production of ACh in various tis-
sues; a non-neuronal cholinergic system. ACh
receptors are present in parallel. The effects of
non-neuronal  ACh  are  related  to  autocrine/
paracrine effects and effects on angiogenesis,
cell proliferation, wound-healing, and inflam-
mation. Our recent observations on the situa-
tion in tendinosis, RA, and OA show that there
is an unexpected presence of a non-neuronal
cholinergic system in these conditions. This
means  that  new  ideas  for  interference  with
cholinergic  effects  are  indeed  welcome  for
these situations. 
What should be the focus for further studies
evaluating the usefulness of interfering with
cholinergic  effects  in  various  parts  of  the
body? One field that should be further exam-
ined is the development of selective nicotinic
agonists  for  man.  The  fact  that  selective
α7nAChR agonists have been found to have
positive effects in a dextran sulphate-induced
colitis model for mice
101 supports a suggestion
that such agonists may be useful in inflamma-
tory disorders. The idea that the α7nAChR is a
target of importance in RA is discussed in the
present review. 
Another field that should be further concen-
trated on is research on the possible useful-
ness of AChE inhibitors in peripheral inflam-
matory  disorders.
64,65 Questions  related  to
selectivity  and  specificity  are,  however,  also
warranted in this case. 
In conclusion, knowledge of the occurrence
of a marked local signal substance production
within a diseased tissue, and the occurrence of
receptors for the substances within the tissue,
is on the whole of great importance for estab-
lishing new possible treatment strategies. It is
obvious that it is not necessary that choliner-
gic nerves are present in order to make ACh
available for the tissue; the substances can be
locally  produced.  This  means  that  not  only
should the neuronal but also the non-neuronal
cholinergic system be taken into consideration
when considering new treatments interfering
with cholinergic effects. This includes disor-
ders related to orthopedics, namely tendinosis,
RA and OA. 
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